

3/30/04

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Not Yet Assigned	
			Filing Date	March 30, 2004	
			First Named Inventor	John McMichael	
			Art Unit	To Be Assigned 1614	
			Examiner Name	To Be Assigned R. Henley	
Sheet	1	of	3	Attorney Docket Number	13024/38628A

U.S. PATENT DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
[Signature]	A1	4,384,993	05-24-1983	Sato et al.
	A2	4,692,331	09-08-1987	Uemura et al.
	A3	5,645,998	07-08-1997	Atkinson et al.
	A4	5,762,937	06-09-1998	Atkinson et al.
	A5	5,792,620	08-11-1998	Lernmark et al.
	A6	6,001,360	12-14-1999	Atkinson et al.
	A7	6,011,139	01-04-2000	Tobin et al.
	A8	6,025,176	02-15-2000	Lernmark et al.
	A9	6,187,309	02-13-2001	McMichael et al.
	A10	6,294,171	09-25-2001	McMichael et al.
	A11	6,300,089	10-09-2001	Atkinson et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Country
		Country Code ² -Number ³ -Kind Code ⁴ (if known)		
[Signature]	B1	CA -2,232,834	03-27-1997	CA
	B2	WO 92/20811	11-26-1992	PCT
	B3	WO 97/10847	03-27-1997	PCT

Examiner Signature	[Signature]	Date Considered	6/7/05
--------------------	-------------	-----------------	--------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Not Yet Assigned 10/813,661		
		Filing Date	March 30, 2004		
		First Named Inventor	John McMichael		
		Group Art Unit	To Be Assigned 1614		
		Examiner Name	To Be Assigned R. Henley		
Sheet	2	of	3	Attorney Docket Number	13024/38628A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s); publisher, city and/or country where published.	T ²
	C1	Blanas <i>et al.</i> , "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen," <i>Science</i> , 274:1707-1709 (1996).	
	C2	Graves <i>et al.</i> , "Lack of Association Between Early Childhood Immunizations and β -Cell Autoimmunity," <i>Diabetes Care</i> , 22:1694-1697 (1999).	
	C3	Kaufman <i>et al.</i> , "Spontaneous Loss of T-Cell Tolerance to Glutamic Acid Decarboxylase in Murine Insulin-Dependent Diabetes," <i>Nature</i> , 366: 69-72(1993).	
	C4	Tian <i>et al.</i> , "Modulating Autoimmune Responses to GAD Inhibits Disease Progression and Prolongs Islet Graft Survival in Diabetes-Prone Mice," <i>Nat. Med.</i> , 2:1348-1353 (1996).	
	C5	Tisch <i>et al.</i> , "Immune Response to Glutamic Acid Decarboxylase Correlates with Insulinitis in Non-Obese Diabetic Mice," <i>Nature</i> , 366:72-75 (1993).	
	C6	Ramiya <i>et al.</i> , "Effect of Oral and Intravenous Insulin and Glutamic Acid Decarboxylase in NOD Mice," <i>Autoimmunity</i> , 26:139-151 (1997).	
	C7	Song <i>et al.</i> , "Human Insulin B Chain but not A Chain Decreases the Rate of Diabetes in BB Rats," <i>Diabetes Research and Clinical Practice</i> , 46:109-114 (1999).	
	C8	Asperger, "Die Psychopathologie des Coeliakakranken Kindes," <i>Ann. Pediatr.</i> , 197:346-351 (1961).	
	C9	Barker <i>et al.</i> , "A Role for Complement in the Rejection of Porcine Ventral Mesencephalic Xenografts in a Rat Model of Parkinson's Disease," <i>J. of Neuroscience</i> , 20:3415-3424 (2000).	
	C10	DiFiglia <i>et al.</i> , "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain," <i>Science</i> , 277:1990-1993 (1998).	
	C11	Dirkx <i>et al.</i> , "Targeting of the 65-kDa Isoform of Glutamic Acid Decarboxylase to Intracellular Organelles is Mediated by Its Interaction with the NH ₂ -terminal Region of the 65-kDa Isoform of Glutamic Acid Decarboxylase," <i>J. Biol. Chem.</i> , 270:2241-2246 (1995).	
	C12	Fahn <i>et al.</i> , "Double-Blind Controlled Trial of Human Embryonic Dopaminergic Tissue Transplants in Advanced Parkinson's Disease: Clinical Outcomes," <i>Neurology</i> , 52:A405 (1999).	
	C13	Heiser <i>et al.</i> , "Inhibition of Huntingtin Fibrillogenesis by Specific Antibodies and Small Molecules: Implications for Huntington's Disease Therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 97:6739-6744 (2000).	
	C14	Kopyov <i>et al.</i> , "Safety of Intrastriatal Neurotransplantation for Huntington's Disease Patients," <i>Exp. Neurol.</i> , 149:97-108 (1998).	

Examiner Signature		Date Considered	4/7/05
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	Not Yet Assigned 10/813,661	
			Filing Date	March 30, 2004	
			First Named Inventor	John McMichael	
			Group Art Unit	To Be Assigned	
			Examiner Name	To Be Assigned	
Sheet	3	of	3	Attorney Docket Number	13024/38628A

	C15	Kordower et al., "Intravenous Administration of a Transferrin Receptor Antibody-nerve Growth Factor Conjugate Prevents the Degeneration of Cholinergic Striatal Neurons in a Model of Huntington Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 91:9077-9080 (1994).	
	C16	Lecerf et al., "Human Single-chain Fv Intrabodies Counteract <i>in situ</i> Huntingtin Aggregation in Cellular Models of Huntington's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 98:4764-4769 (2001).	
	C17	Martin et al., "Regulatory Properties of Brain Glutamate Decarboxylase (GAD): The Apoenzyme of GAD is Present Principally as the Smaller of Two Molecular Forms of GAD in Brain," <i>J. Neuroscience</i> , 11:2725-2731 (1991).	
	C18	Namchuck et al., "Phosphorylation of Serine Residues 3, 6, 10, and 13 Distinguishes Membrane Anchored from Soluble Glutamic Acid Decarboxylase 65 and is Restricted to Glutamic Acid Decarboxylase 65a*," <i>J. Biol. Chem.</i> , 272:1548-1557 (1997).	
	C19	Peltola et al., "No Evidence for Measles, Mumps, and Rubella Vaccine-Associated Inflammatory Bowel Disease or Autism in a 14-Year Prospective Study," <i>Lancet</i> , 351:1327-1328 (1998).	
	C20	Porter et al., "Transaminations Catalysed by Brain Glutamate Decarboxylase," <i>Biochem J.</i> , 231:705-712 (1985).	
	C21	Qu et al., "Motifs and Structural Fold of the Cofactor Binding Site of Human Glutamate Decarboxylase," <i>Protein Science</i> , 7:1092-1105 (1998).	
	C22	Comi et al., "Familial Clustering of Autoimmune Disorders and Evaluation of Medical Risk Factors in Autism," <i>J. of Child Neurology</i> , 14:388-394 (1999).	
	C23	Wakefield et al., "Ileal-lymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in Children," <i>Lancet</i> , 351:637-641 (1998).	
	C24	Walker-Smith et al., "Alpha-1-Antitrypsin, Autism, and Coeliac Disease," <i>Lancet</i> , ii:883-884 (1972).	
	C25	D'Eufemia et al., "Abnormal Intestinal Permeability in Children with Autism," <i>Acta Paediatrica</i> , 85:1076-1079 (1996).	
	C26	Warren et al., "Elevated Serotonin Levels in Autism: Association with the Major Histocompatibility Complex," <i>Neuropsychobiology</i> , 34:72-75 (1996).	
	C27	Weiss, R.A., "Xenografts and Retroviruses," <i>Science</i> , 285:1221-1222(1999).	

Examiner Signature		Date Considered	6/7/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/813,661-Conf. #5210
				Filing Date	March 30, 2004
				First Named Inventor	John McMichael
				Art Unit	1614
				Examiner Name	Not Yet Assigned <i>R. Henley</i>
Sheet	1	of	1	Attorney Docket Number	13024/38628A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number+Kind Code ² (if known)			
<i>[Signature]</i>	A12	4,521,405-A	06-04-1985	McMichael	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
<i>[Signature]</i>	B4	EP 0 123 375	10-31-1984	The Green Cross Corporation		
	B5	FR 3.408M	07-05-1965	Plissier		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>	C28	European Examination Report dated July 6, 2004 in corresponding EPO application no. 0930402.3.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>[Signature]</i>	Date Considered	4/7/05
-----------------------	--------------------	--------------------	--------